Axon 1113
CAS [199467-52-2]
MF C27H39ClN2O2.2HClMW 531.99
Na+ channel blocker; neuroprotective agent.
KEYWORDS: AM 36 dihydrochloride | supplier | Na+ channel Blocker | CNSB002 | AM36 |CAS[199467-52-2] | Sodium | Blocker | Ion Channels | Nav1.3 | Nav1.7 | Nav1.8 | neuropathic pain | analgesic | neuroprotective |ROS
J. K. Callaway et al.Delayed Treatment With AM-36, a Novel Neuroprotective Agent, Reduces Neuronal Damage After Endothelin-1–Induced Middle Cerebral Artery Occlusion in Conscious Rats.Stroke. 1999, 30, 2704-2712. |
J. KCallaway et al. Incorporation of sodium channel blocking and free radical scavenging activities into a single drug, AM-36, results in profound inhibition of neuronal apoptosis. Br. J. Pharmacol. 2001, 132, 1691–1698. |
A. Kolosov et al. Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain. Pain Med. 2010 Jan;11(1):106-18. |
2,6-Di-tert-butyl-4-{4-[2-(4-chloro-phenyl)-2-hydroxy-ethyl]-piperazin-1-ylmethyl}-phenol dihydrochloride
[199467-52-2]
Axon Medchem的业务之一,是独有的Axon Ligands配体库,在世界范围内,被认为是药物研发的标准。这其中,针对850余种生物靶标(包括细胞信号、基因转录、凋亡、细胞周期调控、CNS等),Axon Medchem拥有多达2000余种小分子抑制剂或调节剂。除了配体库,Axon Medchem还是欧洲著名的CRO公司,主要针对生物活性分子和药物类似分子展开合成及协议开发工作,在过去的10年中,Axon Medchem已经发现了多种潜在药物分子,并在生物医药界享有一定的声誉。